News Room Archive
July 8, 2008 - FDA Approves EOVIST® to Detect and Characterize Focal Liver Lesions
WAYNE, NJ July 8, 2008 - Bayer HealthCare Pharmaceuticals Inc., a leader in diagnostic imaging, announced today that the U.S. Food and Drug Administration (FDA) has approved EOVIST®
See More
July 2, 2008 - Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen
Leverkusen / Redwood City, California, USA, July 2, 2008 - Bayer HealthCare is expanding its commitment to hemophilia with the acquisition of Maxygen's hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII.
See More
June 24, 2008 - Bayer concludes supply and licensing agreements for Yasmin® and YAZ®
Berlin/Leverkusen, June 24, 2008 - Appeal of court decision invalidating Yasmin patent will continue. Further growth of Bayer's Women's Healthcare Business Unit expected.
See More
June 5, 2008 - Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
WAYNE, N.J., June 5, 2008 -Results from an adjuvant trial in high-risk melanoma patients demonstrated that a majority of patients treated with Leukine(R) (sargramostim) achieved disease-free and/or overall survival. These findings, which indicate Leukine's potential in this cancer setting, were released at the 44th annual meeting of the American Society of Clinical Oncology (ASCO).
See More
May 28, 2008 - Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen, New Survey Reveals
Denver, CO - May 28, 2008 - Nearly all people (97 percent) with multiple sclerosis (MS) who have started treatment say their commitment to managing their disease in every way possible is their prime motivation for staying on therapy, according to a new North American survey of people with MS, results of which were released today at the Consortium of Multiple Sclerosis Centers annual meeting in Denver.
See More
May 19, 2008 - Hemophilia Awareness and Fundraising Program Accelerates with Launch of 2008 Campaign
NEW YORK, NY - May 19, 2008 - The National Hemophilia Foundation (NHF) shifts into high gear today with the launch of Team Hemophilia on Tour, a fundraising and awareness program sponsored by Bayer HealthCare and supported by Andretti Green Racing.
See More
May 19, 2008 - Bayer Announces Availability of Reformulated Liquid Leukine®
Wayne, NJ - May 19, 2008 - Bayer HealthCare Pharmaceuticals Inc. announced today that a reformulation of the liquid Leukine® (sargramostim) 500 mcg vial has been approved by the United States Food and Drug Administration (FDA) and is now available for patients and physicians in the U.S.
See More
April 30, 2008 - Aspiring young designers give YAZ® birth control case a makeover
Nina Garcia of the Emmy-nominated series "Project Runway" and Elle magazine is calling upon designer hopefuls everywhere to submit contemporary and fashionable packaging concepts for the oral contraceptive YAZ® (drospirenone & ethinyl estradiol).
See More
31 March 2008 - Bayer appeals invalidity ruling on its Yasmin® Patent
Leverkusen, March 31, 2008 - Today, Bayer filed a Notice of Appeal in the United States District Court for the District of New Jersey
See More
11 March 2008 - Bayer HealthCare Pharmaceuticals Introduces VistaTrak™ An Innovative Contrast Media Management System
WAYNE, NJ – March 11, 2008 – Bayer HealthCare Pharmaceuticals Inc., a leader in diagnostic imaging, unveiled plans to launch VistaTrak™, an innovative contrast media management system that provides radiology departments with a new and powerful management tool to help enhance patient care and safety, optimize inventory management and improve billing accuracy.
See More
3 March 2008 - Court decides against Bayer's Yasmin® patent
See More
18 February 2008 - Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients with Non-Small Cell Lung Cancer
Wayne, NJ and Emeryville, CA – (February 18, 2008) – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar® (sorafenib) tablets in patients with non-small cell lung cancer (NSCLC) was stopped early following a planned interim analysis, when the independent Data Monitoring Committee (DMC) concluded that the study would not meet its primary endpoint of improved overall survival. The Phase 3 ESCAPE (Evaluation of Sorafenib, Carboplatin And Paclitaxel Efficacy in NSCLC) trial evaluated Nexavar when administered in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Safety events were generally consistent with those previously reported. However, higher mortality was observed in the subset of patients with squamous cell carcinoma of the lung treated with sorafenib and carboplatin and paclitaxel versus those treated with carboplatin and paclitaxel alone.
See More
5 February 2008 - Bayer HealthCare Awards Grant to Support Future Leaders of Bleeding Disorders Community
BERKELEY, Calif. – (February 5, 2008) – Bayer HealthCare today announced its donation of a $100,000 grant to help the National Hemophilia Foundation (NHF) fund activities for its National Youth Leadership Institute (NYLI), a program designed to develop the next generation of leaders within the bleeding disorders community. The contribution, made by the Bayer USA Foundation, marks the second year of support for this important program.
See More
23 January 2008 - Bayer Establishes US Special Access Program for Leukine® While Replacing Current Liquid Formulation
Wayne, NJ – Bayer HealthCare Pharmaceuticals Inc. announced today, following consultation with the United States Food and Drug Administration (FDA), that it will withdraw the current liquid formulation of Leukine® marketed in the US. This decision was made in light of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with the liquid Leukine 500 mcg vial which currently contains EDTA (edetate disodium).
See More
17 January 2008 - US Food and Drug Administration Approves RECOTHROMTM
See More
3 January 2008 - Expanded Labeling for MabCampath® in Europe
Berlin, January 3, 2008 – The European Commission has granted marketing authorization to MabCampath® (alemtuzumab) for the treatment of patients with B-cell chronic lymphocytic leukemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate.
See More
20 December 2007 - Marketing of Viadur® (leuprolide acetate implant) to Phase Out By April 2008
Other therapies available for patients
Wayne, NJ. - Bayer HealthCare Pharmaceuticals Inc. announced today that after careful consideration, the company will discontinue marketing of Viadur® (leuprolide acetate implant) with Duros technology. Based on diminished market demand and growing manufacturing costs, Bayer HealthCare Pharmaceuticals has concluded that Viadur has limited long-term market viability. The decision to discontinue marketing of Viadur is not the result of safety or efficacy issues.
See More
05 December 2007 - Positive CHMP vote for Betaferon® label to include disability progression delay in patients with the earliest sign of MS
Betaferon® is first and only MS therapy to delay disability in patients treated after first MS attack
Berlin - The Committee for Medicinal Products for Human Use (CHMP) has recommended to include new results from the landmark BENEFIT (BEtaferon in Newly Emerging multiple sclerosis For Initial T reatment) study in the Betaferon® (interferon beta-1b) label.
See More
20 November 2007 - Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
WAYNE, N.J., - Bayer HealthCare Pharmaceuticals, Inc a leader in diagnostic imaging, announced today that the company has been awarded a three-year contract by MedAssets Supply Chain Systems, one of the nation's largest group purchasing organizations, to provide Magnevist(R) (gadopentetate dimeglumine) Injection contrast media to members of the MedAssets network. MedAssets serves more than 125 health systems, including 2,500 hospitals and 30,000 non-acute care healthcare providers
See More
19 November 2007 - Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Only Systemic Therapy Proven to Significantly Improve Overall Survival in Patients with Liver Cancer
Wayne, NJ and Emeryville, CA - Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application for Nexavar® (sorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC), or liver cancer.
See More
07 November 2007 - BRIGHT Results Show Less Pain and Higher Patient Satisfaction with Betaseron® than with Rebif®
Study shows injection site pain can negatively influence patient satisfaction with treatment
Wayne, NJ. - Patients with relapsing-remitting multiple sclerosis (MS) treated with 250 mcg Betaseron (interferon beta-1b) experienced less injection site pain and fewer injection site reactions than those treated with 44 mcg Rebif. Moreover, among those who experienced injection site pain, significantly more patients on Rebif versus Betaseron said that pain negatively influences their satisfaction with treatment.
See More
05 November 2007 - Bayer Temporarily Suspends Global Trasylol® Marketing
Leverkusen, Germany and West Haven, CT, USA - Following consultation with the German Federal Institute for Drugs and Medical Devices (BfArM), the U.S. Food and Drug Administration (FDA), Health Canada, and other health authorities, Bayer announced today that it has elected to temporarily suspend worldwide marketing of Trasylol® (aprotinin injection) until final results from the Canadian BART trial can be compiled, received and evaluated.
See More
30 October 2007 - Nexavar® Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
Wayne, NJ and Emeryville, CA - Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the European Commission has granted marketing authorization to Nexavar® (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), or liver cancer.
See More
29 October 2007 - BEYOND study: Results do not support regulatory filing for Betaferon® 500 mcg
Berlin, Germany - Bayer Schering Pharma AG, Germany, today announced top line results from the BEYOND (Betaferon Efficacy Yielding Outcomes of a New Dose) study, a large randomized trial of patients with relapsing-remitting multiple sclerosis (MS) to investigate the efficacy, tolerability and safety of a 500 mcg dose of Betaferon® (interferon beta-1b) compared to the standard 250 mcg Betaferon® dose and Copaxone® (glatiramer acetate).
See More
26 - October - New Survey Finds Technology Plays a Critical Role in the Lives of People with Multiple Sclerosis Yet Many Are Not Using It to Overcome Disease-Related Challenges
-- Affordable, Easy-to-Use Accessible Technology is Within Reach for People with MS --
DALLAS, OCTOBER 26, 2007 -- According to a new survey released this week in conjunction with the National MS Society's National Conference, many people living with multiple sclerosis (MS) who experience visual, dexterity, and cognitive challenges report that technology plays a vital role in helping them live with the disease. However, relatively few are using the assistive technologies that could help them overcome many of these challenges
See More
25 October 2007 - Bayer Issues Additional Guidance to Physicians on Trasylol®
Leverkusen, Germany and West Haven, CT, USA - Today Bayer announced new guidance to physicians and health care providers regarding the use of Trasylol® (aprotinin injection) in patients at an increased risk of blood loss and blood transfusion undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB).
See More
23 October 2007 - Red Hot Flashbacks: Celebrity Stylist Yang & Red Hot Mamas Giblin Share How to Keep “Cool” During “Red Hot” Menopausal Moments
WAYNE, N.J. Oct 23, 2007 - For many active, on-the-go women, menopause symbolizes uncomfortable and disruptive symptoms, such as hot flashes and night sweats.
See More
01 October 2007 - Bayer HealthCare Announces Positive Phase 2 Results for the VEGF Trap-Eye
Age-related Macular Degeneration (AMD) - Data presented at the Retina Society Conference in Boston
Leverkusen, Germany –Bayer HealthCare and development partner Regeneron Pharmaceuticals, Inc. today announced positive results from a Phase 2 study evaluating the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD), one of the leading causes of blindness in adults.
See More
26 September 2007 - Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
CAMBRIDGE, Mass. and BERLIN, Germany – Genzyme Corporation (Nasdaq: GENZ) and Bayer Schering Pharma AG, Germany today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS).
See More
24 September 2007 - Nexavar Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Treatment of Liver Cancer
Wayne, NJ and Emeryville, CA – Bayer HealthCare Pharmaceuticals (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending to grant marketing authorization for Nexavar® (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), or liver cancer.
See More
20 September 2007 - FDA Approves Expanded Labeling for Campath® to Include First-line Treatment for Leading Form of Adult Leukemia
Study Data Demonstrated Improved Progression-free Survival with Campath
Cambridge, MA and Wayne, NJ – Genzyme Corp. (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for Campath® (alemtuzumab) and granted regular approval for single-agent Campath for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).
See More
14 September 2007 - Bayer completes acquisition of U.S. biologics manufacturing facility from Novartis
Berlin, Germany — Bayer Schering Pharma AG, Germany, has completed the acquisition of a biologics manufacturing facility in Emeryville, California from Novartis. Bayer will manufacture its multiple sclerosis drug Betaseron® at the Emeryville site, retain full control of all manufacturing and process technology used in the production of Betaseron® (interferon beta-1b) and has retained the employees associated with the manufacture of the product.
See More
12 September 2007 - FDA Advisory Committees Recommend Continued US Marketing Authorization for Trasylol
Committees also recommend further changes
to US Label for Trasylol and additional safety studies
Leverkusen, Germany; West Haven, CT, USA -- Today, the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to the U.S. Food and Drug Administration (FDA) held a meeting to discuss the risk /benefit profile of Trasylol® (aprotinin injection), a Bayer drug used in coronary artery bypass graft (CABG) surgery.
See More
27 August 2007 - Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Nexavar Significantly Improved Overall Survival in Phase 3
Asia-Pacific Liver Cancer Trial
Trial to be Stopped Early to Allow All Patients Access to Nexavar-
Wayne, NJ and Emeryville, CA - August 27, 2007 - Bayer HealthCare Pharmaceuticals (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a planned review by an independent data monitoring committee (DMC) found that Nexavar® (sorafenib) tablets significantly improved overall survival, progression free survival, and time to progression in an Asia-Pacific regional Phase 3 trial of patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer.
See More
20 August 2007 - Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
Wayne, NJ and Emeryville, CA – Bayer HealthCare Pharmaceuticals (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the supplemental New Drug Application (sNDA) for Nexavar® (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, has been accepted for review and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
16 August 2007 - Bayer Reports Findings of Trasylol Independent Investigation
Investigator Report
Key Committees - Bayer Global Drug Safety
Leverkusen, Germany and West Haven, Connecticut, USA. Today, Bayer HealthCare reported findings of Mr. William Taylor's independent investigation on the i3 Drug Safety observational study on Trasylol® (aprotinin injection) to the U.S. Food and Drug Administration (FDA) and other relevant regulatory authorities and also conveyed actions the company has taken to ensure that this sort of mistake is never again repeated.
See More
2 August 2007 - Landmark Study in The Lancet:Patients Treated With Betaseron® After First MS Attack Experienced Significant Delay in MS Progression WAYNE, NJ – August 2, 2007 – Patients treated with Betaseron® (interferon beta-1b) shortly after their first clinical MS event or “attack” showed a 40 percent lower risk of developing confirmed disability progression compared to patients in whom treatment was delayed.
See More
12 July 2007 - YAZ approved in the Netherlands as European Reference Member State
YAZ is the newest oral contraceptive innovation from Bayer Schering Pharma
Berlin — Bayer Schering Pharma AG, Germany, announced today that the Dutch regulatory authorities have granted national approval for their new low dose 24-day oral contraceptive YAZ® in the Netherlands.
See More
09 July 2007 - Rivaroxaban shows superiority over current standard of care therapy
Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor, Shows a Significant Reduction in Deep Vein Thrombosis and Pulmonary Embolism Compared with Enoxaparin with Similarly Low Bleeding Rates
See More
29 June 2007 - Bayer HealthCare Announces New 2000 IU Vial Size for Kogenate® FS Treatments
Larger vial size, new Grab & Go package help to reduce reconstitution time and provide added convenience for people living with hemophilia A
Berkeley/USA — Bayer HealthCare announces today the availability of a new 2000 IU (international unit) vial size in the United States for hemophilia A patients treated with Kogenate® FS, Antihemophilic Factor (Recombinant), and Kogenate® FS Antihemophilic Factor (Recombinant), with BIO-SET®, a Needleless Reconstitution System
See More
27 June 2007 - Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Nexavar is First Drug Therapy to Demonstrate Significant Survival Benefit in Liver Cancer
Wayne, NJ/USA — Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Supplemental New Drug Application (sNDA) for Nexavar® (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer.
See More
04 June 2007 - Phase 3 Study: Nexavar® Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Berlin - June 4, 2007 - Bayer HealthCare, a subsidiary of Bayer AG (NYSE:BAY), and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced thatNexavar® (sorafenib) tablets significantly extended overall survival in patients with hepatocellular carcinoma (HCC), or primary liver cancer versus those taking placebo by 44%.
See More
07 May 2007 - Bayer HealthCare and Intendis Announce Strategic Alliance To Co-promote YAZ® (drospirenone/ethinyl estradiol) for Treatment of Moderate Acne
Alliance Announced as Yaz Acne Clinical Trial Data Presented at 55th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG)
03 May 2007 - Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron®
Bayer HealthCare Pharmaceuticals announced today the results of three clinical studies with Betaseron (interferon beta-1b), presented this week at the American Academy of Neurology’s (AAN) 59th Annual Meeting, demonstrating early efficacy, long-term tolerability, and high patient satisfaction with treatment in patients with relapsing forms of multiple sclerosis (MS). See More
02 May 2007 - Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
Interim analysis of Phase 2 comparative study showed significant results in favor of alemtuzumab versus Rebif®
01 May 2007 - First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron®
Significantly Delayed Permanent Disability Risk to confirmed EDSS progression reduced by 40 percent compared to delayed treatment
11 April 2007 - Bayer supports the WHO in its fight against Chagas disease
Partnership with the World Health Organization (WHO) to continue
05 April 2007 - Indy Racing Season Drives New Support for Marco Andretti and Team Hemophilia
Indy Racing Season Drives New Support for Marco Andretti and Team Hemophilia
04 April 2007 - Genzyme Files for Expanded Label for Campath® as First-Line Treatment
Genzyme Files for Expanded Label for Campath® as First-Line Treatment For B-CLL Patients
04 April 2007 - Bayer HealthCare Pharmaceuticals Officially Launches in the United States
Bayer HealthCare Pharmaceuticals Officially Launches in the United States
02 April 2007 - Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment
The largest dataset ever analyzed on the relevance of NAbs to interferon beta therapy.
15 March 2007 - Werner Wenning at the Spring Financial News Conference
2006 a record year for Bayer
20 February 2007 - Bayer HealthCare strengthens presence in Eastern Europe
More than 200 staff for Marketing and Sales integrated in Russia, Belarus, the Ukraine and Kazakhstan
12 February 2007 - Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
Trial To Be Stopped Early Based on Positive Outcome See More
08 February 2007 - EU-Approval for Continuous Infusion of KOGENATE® Bayer
Excellent Hemostatic Control Achieved.
13 December, 2006 - Bayer donates antibiotics with a wholesale value of more than US$ 25 million to MAP International for Africa and Latin America
The aid organization will distribute the critically needed antibiotic to clinics and hospitals in Africa and Latin America that are fighting on the front lines in the battle against diseases of poverty where there is little or no access to essential medicines.
11 December 2006 - Data From Phase III Comparative Study Show Campath(R) Superior to Chlorambucil as a First-line Therapy in
B-CLL
Study met primary endpoint of progression free survival with Campath
27 November 2006 - Wenning: Schering acquisition provides additional boost to Bayer
Fall Financial News Conference 2006 of Bayer AG
09 November 2006 - Bayer Outlines New Global R&D Structures; U.S. Pharma Sites and Future Headquarters
Bayer HealthCare announced today a structural realignment of its global pharmaceutical research and development organization.
08 November 2006 - Bayer and Ortho-McNeil, Inc. Outline Phase III Study Program of Oral Factor Xa Inhibitor Rivaroxaban in Chronic Indications
Patient Recruitment for Phase III Clinical Trial to Start in Studies of Oral Anticoagulant in Chronic Indications
31 October 2006 - Bayer’s Perspective on Innovation 2006 Wenning: “Research is the key to success”
• Three new patent applications every working day help safeguard Bayer’s future
• Technology of the future: plant-made pharmaceuticals
• Group-wide innovation initiative “Triple-i” successfully launched
31 October 2006 - Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin’s Lymphoma
– Twenty-five study centers currently open across the U.S. –
26 October 2006 - What Do Doctors Know and Women Don't?
The IUC is a Preferred Contraceptive of Female Ob/Gyns in the U.S.
23 October 2006 - FDA Approves Betaseron for Use After the First Event Suggestive of Multiple Sclerosis
Early treatment with Betaseron significantly delayed the time to a second clinical event
18 October 2006 - Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases
Regeneron Retains U.S. Commercialization Rights, Receives $75 Million Upfront, and Eligible for up to $245 Million of Milestone Payments
05 October 2006 - FDA Approves new Indication for YAZ® to Treat Emotional and Physical Symptoms of Premenstrual Dysphoric Disorder (PMDD)
YAZ is the First and Only Birth Control Pill With Proven Efficacy for PMDD
09 September 2006 - Schering acquisition: Bayer reaches squeeze-out threshold
Bayer has purchased further shares of Schering on the stock market and on Friday, September 8, 2006 increased its holding to more than 95 percent, the proportion required to effect a “squeeze-out” of minority stockholders.
31 July 2006 - Berlex Voluntarily Recalls Ultravist® Injection 370 mgI/mL
Berlex, Inc., a US affiliate of Schering AG, Germany, is voluntarily recalling all lots of its X-ray contrast agent Ultravist® Injection 370 mgI/mL (iopromide injection), as part of a worldwide recall, due to the potential that particulate matter in conjunction with crystallization may be present in the product.
See More
23 July 2006 - Nexavar® Approved by European Commission for the Treatment of Advanced Kidney Cancer
Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc. today announced that the European Commission has granted marketing authorization to Nexavar® (sorafenib) tablets
See More
21 July 2006 - Berlex Issues Nationwide Recall of a Single Lot of ULTRAVIST® Injection 370 mgI/mL, 125 mL in the U.S.
Berlex, Inc. has initiated a nationwide recall of a single lot (No. 41500A) of its intravenous X-ray contrast agent, Ultravist® Injection 370 mgI/mL, 125 mL, (iopromide injection) NDC 50419-346-12, EXP 01/2007, due to the presence of particulate matter in conjunction with crystallization.
See More
18 July 2006 - Bayer HealthCare and BioRx Introduce Educational Children’s Book About Hemophilia The Great Inhibinator is an inspiring story that will be a valuable teaching tool for parents and healthcare providers dealing with inhibitors
See More
17 July 2006 - Bayer HealthCare Introduces Free Product Trial Program For Kogenate® FS with BIO-SET
Individuals living with hemophilia A in the United States can now experience the safety, simplicity, and convenience of treatment with the first needleless reconstitution device for rFVIII treatment
See More
11 July 2006 - New Autoinjection Device Designed to Work with Betaseron now Available for Patients with Multiple Sclerosis
Betaject®3 Offers Convenient Delivery Option
See More
10 July 2006 - New Study Reveals Barriers to Reproductive Health Care in US Latino Community
Communication Among Couples and Improved Education Needed
See More
26 June 2006 - Washington University and Berlex Collaborate on Research Fellowship
Today Berlex, Inc., announced a collaboration with the Mallinckrodt Institute of Radiology at the Washington University School of Medicine in St. Louis that includes the creation of a post-doctoral research fellowship in the field of diagnostic imaging contrast agents.
See More
21 June 2006 - Company’s biggest-ever transaction successful!
Bayer and Schering optimistic about their common future
See More
14 June 2006 - Pfizer Signs Agreement with Bayer to License Compounds for Potential Treatment of Obesity, Diabetes and Related Disorders
Pfizer Inc. and Bayer Pharmaceuticals Corporation, the U.S. subsidiary of Bayer HealthCare, announced today that they have entered into an agreement granting Pfizer exclusive worldwide rights to Bayer's DGAT-1 inhibitors, an innovative class of compounds that modify lipid metabolism.
See More
13 June 2006 - Nexavar Receives Fast Track Designation from the FDA for Metastatic Liver Cancer
The updated analysis confirmed that overall survival was longer for Nexavar than for placebo patients.
See More
07 June 2006 - New Survey Suggests Couples May Need Help Keeping Their Romance Alive This Summer
Today's demanding lifestyles make it a challenge for couples to feel free to be romantic – especially for parents who have even less time together now that kids are out of school for the summer.
See More
05 June 2006 - Updated Overall Survival Analysis Presented on Nexavar Phase III Trial
The updated analysis confirmed that overall survival was longer for Nexavar than for placebo patients.
See More
03 June 2006 - Genzyme and Berlex Oncology Announce Interim Results of Campath in First-Line Study of Chronic Lymphocytic Leukemia at ASCO
Initial data from a Phase III comparative study suggest efficacy and safety with Campath®, even in poor-prognosis patients
See More
25 May 2006 - Bayer HealthCare, The National Hemophilia Foundation, and Andretti Green Racing Announce Racing for Hemophilia Primary Donor for the 2006 Indianapolis 500
Successful program raised money and awareness for hemophilia A
See More
24 May 2006 - Promising Early Clinical Trials for Bayer’s Longer Acting Kogenate® Product
Data from two early-stage clinical trials presented today at the World Federation of Hemophilia (WFH) conference offer promising results and support further development for a new experimental factor VIII replacement product, BAY 79-4980.
See More
23 May 2006 - Bayer Grant Promotes Groundbreaking Hemophilia Research and Education
Bayer Hemophilia Awards Program continues to be a critical source of funding for hemophilia research and education
See More
22 May 2006 - New study data confirm excellent speed of eradication by Avelox® (moxifloxacin HCl)
Complete eradication of pathogens in acute bacterial sinusitis after only three days of treatment
See More
3 May 2006 - Enrollment Completed in Phase III Studies of Nexavar for Patients with Metastatic Melanoma and Liver Cancer
Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc. today announced the completion of patient enrollment in two randomized, double-blind Phase III clinical trials; one administering Nexavar® (sorafenib) tablets in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with advanced metastatic melanoma and another administering Nexavar as a single agent in patients with advanced hepatocellular carcinoma (HCC), or liver cancer.
See More
28 April 2006 - Nexavar® Receives Positive Opinion from European Committee for Medicinal Products
for Human Use
Renal Cell Carcinoma Approval Received in Mexico
See More
27 April 2006 - Experts recommend Aspirin® for the treatment of migraine
The active ingredient acetylsalicylic acid (ASA) provides safe, reliable relief
See More
27 April 2006 - GIANT Study: Many more women affected by acute exacerbations of chronic bronchitis (AECBs) than widely believed
Largest ever antibiotic study sheds new light on AECBs and confirms effective antibiotic therapy with Avelox® can reduce the significant negative impact on patients’ quality of life
See More
27 April 2006 - Bayer achieves record earnings
Interim report for the first quarter of 2006
See More
26 April 2006 - FDA Grants Orphan Drug Designation to Nexavar for the Treatment of Hepatocellular Carcinoma Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that Nexavar® (sorafenib) tablets has been granted orphan drug status for the treatment of hepatocellular carcinoma (HCC), or liver cancer, by the U.S. Food and Drug Administration (FDA).
See More
19 April 2006 - New YAZ® Oral Contraceptive Available in the United States
New YAZ® Oral Contraceptive Available in the United States
See More
18 April 2006 - European Commission Grants Orphan Medicinal Product Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that Nexavar® (sorafenib) tablets has been granted orphan medicinal product status for the treatment of hepatocellular carcinoma (HCC), or liver cancer, by the European Commission.
See More
13 April 2006 - Bayer makes official takeover offer for Schering
Acceptance period for the offer of EUR 86 per share ends on May 31, 2006 / Wenning: Offer is a worthwhile one for Schering shareholders
See More
05 April 2006 - As first-line erectile dysfunction treatment for men, Levitra provides sexual satisfaction for couples
In this first study of its kind in men with erectile dysfunction who had not previously been treated with a phosphodiesterase type 5 (PDE5) inhibitor, 81% of men who took Levitra (vardenafil) reported improved erections (81% with Levitra vs 30% who took a placebo; p<0.0001).
See More
04 April 2006 - Sixteen-Year Follow-up Study Reinforces Betaseron® Long-Term Efficacy, Safety and Tolerability in Multiple Sclerosis
Efficacy in relapse rate reduction beyond five years shown for the first time
See More
30 March 2006 - Nexavar Approved in Switzerland for the Treatment of Patients with Advanced Kidney Cancer
First European Approval in New Class of Cancer Therapy
See More
17 March 2006 - FDA Approves Yaz, the First Oral Contraceptive to Offer Drospirenone in a 24-day, Active-Pill Regimen
Berlex, Inc., a U.S. affiliate of Schering AG, Germany (FSE: SCH; NYSE: SHR), announced today that the U.S. Food and Drug Administration (FDA) has approved YAZ® (3 mg drospirenone/20 mcg ethinyl estradiol), a new monophasic oral contraceptive (OC) and the first pill to combine 20 mcg of ethinyl estradiol with the innovative progestin drospirenone (drsp).
See More
24 February 2006 - East meets West when Jerry Hall addresses Asian conference as global ambassador for new erectile dysfunction campaign
Model, actress and icon, Jerry Hall appears alongside renowned sexual specialists at the ‘A Couple’s Solution’ press seminar to encourage men and women globally to Strike Up A Conversation and openly discuss erectile dysfunction with each other and with healthcare professionals.
See More
23 February 2006 -Berlex Files Application for Use of Betaseron in Patients with a First Clinical Episode
Berlex, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of a supplemental biologics license application (sBLA) requesting an expanded label for its multiple sclerosis (MS) therapy, Betaseron® (interferon beta-1b).
See More
16 February 2006 - Bayer and Onyx Initiate Phase III Non-Small Cell Lung Cancer Trial Studying Nexavar (sorafenib) tablets in Combination with Two Chemotherapeutic Agents
West Haven Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc. today announced the initiation of a randomized, double-blind, placebo-controlled Phase III clinical trial studying Nexavar® (sorafenib) tablets administered in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC)
See More
08 February 2006 - IMPORTANT Trasylol Safety Information
This information is for all U.S. Healthcare Professionals!
See More
08 February 2006 - Bayer and Global Regulatory Authorities Evaluating Published Reports on Trasylol
Bayer will publish and mail letters to Health Care Professionals
See More
0 2 February 2006 - Image of Multiple Sclerosis Captured through Photographic Exhibit By Renowned Photographer
The Image of MS Chronicles Personal Stories from Men and Women with MS
See More
25 January 2006 - FDA clarifies status of YAZTM PMDD application
Schering AG, Germany (FSE: SCH, NYSE: SHR) announced today that its U.S. affiliate, Berlex, Inc., has received an approvable letter from the U.S. Food and Drug Administration (FDA) indicating that the premenstrual dysphoric disorder (PMDD) application for YAZ™ is approvable pending their review of recently submitted data and their satisfactory conclusion on its content.
See More
20 January 2006 -Berlex, Amerinet Extend and Enhance Agreement for Contrast Media Therapy Patch, Climara Pro®
Ultravist® Joins Magnevist® as part of Amerinet’s Portfolio of Contracted Contrast Agents
See More
05 January 2006 - Bayer HealthCare and Nuvelo Enter Into Collaboration Agreement for Global Development and Commercialization of Alfimeprase
Product Perfectly Complements Bayer´s Hematology and Cardiology Portfolio
See More
04 January 2006 - FDA Approves Osteoporosis Indication for Once-A-Week Hormone Therapy Patch, Climara Pro®
First and only once-a-week combination patch for osteoporosis
See More
03 January 2006 - Bayer HealthCare purchases Pritor business from GlaxoSmithKline
Strategic fit for Bayer´s pharma business.
See More
